EuroBiotech—More articles of note


> The team tasked with clearing Redx’s debt disclosed how it came to offload a BTK inhibitor to Loxo Oncology for $40 million. Loxo was up against a clutch of other companies in the scrap to buy the drug. But Loxo  was able to beat the competition, having previously held preliminary discussions about the asset, beating the lowball bids of rivals who hadn’t and moving faster than the one other company that had. Filing

> Lundbeck penciled in a fall 2017 completion date for a phase 1 trial of its Alzheimer’s vaccine. The Danish drugmaker wrapped up enrollment in the trial of the vaccine recently, teeing it up to start learning about the clinical safety of a vaccine designed to induce beta-amyloid-targeting antibodies. Report (PDF)

> Zealand Pharma priced its IPO. The Danish biotech offloaded more than 4 million shares at close to $18 a piece, resulting in it grossing $78 million, more than it initially targeted. Zealand will use most of the money to fund clinical development of glepaglutide for the treatment of short bowel syndrome. Release  

> Neovacs raised €6 million in a private placement. The French biotech tapped U.S. institutional investors for the cash, which enables it to complete mid-phase trials of IFNalpha Kinoid in lupus and dermatomyositis. Statement

> A second phase 3 trial of Motif Bio’s iclaprim completed its treatment stage. The milestone moves Motif Bio a step closer to gathering the data it hopes will position it to win approval of the antibiotic. Release  

> Faron Pharmaceuticals’ phase 3 acute respiratory distress syndrome trial came through a meeting of the data monitoring committee. Statement